Why NAD+ Biomarker Changes Do Not Automatically Establish Clinical Outcomes

An increase in NAD+, an NAD-related metabolite, or another biochemical marker can show that an intervention altered a measurable biological pathway, but it does not automatically establish that a person experienced a clinically meaningful outcome. Biomarkers and clinical endpoints answer different questions, and the relationship between them must be demonstrated rather than assumed.

This distinction is essential when interpreting NAD+ research. Human trials of NAD-related interventions often provide clearer evidence of biochemical target engagement than of broad changes in physical function, recovery, cognition, metabolic outcomes, or healthy ageing.

This article is provided for general educational purposes and explains terminology, evidence, and regulatory concepts associated with NAD+ research. It does not establish the regulatory status of any specific InStrips product or determine whether a particular product is appropriate for any person.

A change in blood NAD+, cellular NAD+, NAD-related metabolites, enzyme activity, gene expression, mitochondrial markers, or another laboratory variable does not by itself establish clinical effectiveness, improved energy, faster recovery, disease modification, healthier ageing, or longer life.

What Is a Biomarker?

A biomarker is a measurable characteristic used to investigate a biological process, exposure, response, or health-related state.

Examples in NAD+ research may include:

• whole-blood NAD+
• intracellular NAD+
• NADH
• nicotinamide metabolites
• NMN-related metabolites
• NR-related metabolites
• enzyme activity
• metabolic markers

Different biomarkers can answer different questions.

What Is a Clinical Outcome?

A clinical outcome describes how a participant feels, functions, survives, or experiences a defined health event.

Depending on the research question, outcomes can include:

• exercise capacity
• muscle strength
• physical function
• symptoms
• quality of life
• cognitive performance
• clinical events

A laboratory change and a clinical outcome are not interchangeable measurements.

Biochemical Target Engagement Is an Earlier Evidence Step

If an intervention increases NAD+ or an NAD-related metabolite, it may show that the intervention reached or altered part of the intended metabolic pathway.

This can be scientifically useful.

Further questions remain:

• Which tissue changed?
• How long did the change persist?
• Was the magnitude biologically important?
• Did downstream processes change?
• Did function change?
• Were any adverse effects observed?

A Biomarker Can Change Without a Functional Outcome

Human trials can show a clear biochemical response while functional endpoints remain unchanged.

This can occur because:

• the biomarker is not rate limiting
• the tissue measured is not the critical tissue
• the change is too small
• the change is too brief
• other biological constraints remain
• the outcome requires multiple pathways

More NAD+ Does Not Automatically Mean More Cellular Energy

NAD+ participates in redox reactions involved in cellular metabolism.

This biochemical role is sometimes simplified into the claim that increasing NAD+ necessarily increases a person's energy.

Cellular energy production also depends on:

• substrate availability
• oxygen
• mitochondrial function
• enzyme activity
• ADP availability
• cellular demand
• tissue physiology

An increase in NAD+ therefore does not establish a proportional increase in ATP production or perceived energy.

Cellular Energy Is Not the Same as Feeling Energetic

The word energy can refer to biochemical energy metabolism or to a person's subjective sense of fatigue and vitality.

These are different concepts.

Perceived energy can be influenced by:

• sleep
• mood
• physical activity
• illness
• nutrition
• medications
• expectation

A metabolic biomarker cannot substitute automatically for a validated fatigue or vitality measure.

Blood NAD+ Does Not Establish Muscle NAD+

Whole-blood or plasma measurements are relatively accessible.

Muscle metabolism occurs in a different biological compartment.

A rise in blood NAD+ or related metabolites does not show automatically that skeletal-muscle NAD+ increased by the same amount.

Blood NAD+ Does Not Establish Brain NAD+

The brain has tissue-specific metabolism and biological barriers.

Peripheral NAD-related measurements should not automatically be interpreted as evidence of equivalent changes in the central nervous system.

Claims involving cognition or neurological function require human outcome evidence designed for those questions.

Different Tissues May Respond Differently

Human NAD+ metabolism is tissue specific.

An intervention may produce measurable changes in one tissue while producing smaller, different, or unmeasured changes elsewhere.

This is one reason recent reviews emphasize the limited amount of human tissue-specific evidence.

A Biomarker Must Be Validated for Its Intended Use

A biomarker useful for demonstrating biochemical exposure is not automatically useful for predicting clinical outcomes.

Validation may require evidence that the biomarker:

• can be measured reliably
• changes consistently with the biological process
• predicts an outcome
• responds appropriately to intervention
• adds information beyond other measurements

Whole-Blood NAD+ May Not Be a Reliable General Biomarker of Ageing

Recent human research has challenged the simple assumption that whole-blood NAD+ consistently declines with age.

This matters because an intervention cannot automatically be described as reversing an age-related biomarker if the biomarker itself has not been established as a consistent measure of ageing across humans.

Ageing Is Not One Biochemical Measurement

Human ageing involves changes across multiple systems.

These can include:

• musculoskeletal function
• metabolism
• cardiovascular function
• immune function
• cognition
• frailty
• disease incidence

No single NAD+ measurement establishes the overall rate of biological ageing.

An Increase From Baseline Is Not Automatically Normalization

If NAD+ rises after an intervention, the result may be described as an increase.

Calling it normalization requires additional evidence that:

• baseline levels were abnormal
• a valid normal range exists
• the post-intervention value entered that range
• the range relates to meaningful outcomes

Higher Is Not Automatically Better

A biomarker can have an optimal biological range rather than a simple more-is-better relationship.

A larger increase in NAD+ does not establish:

• greater benefit
• better function
• lower risk
• longer lifespan

Exposure-response relationships need to be studied directly.

Magnitude of Change Requires Context

A study might report a 20%, 50%, or larger increase in an NAD-related measurement.

The interpretation depends on:

• baseline value
• assay method
• biological compartment
• natural variability
• timing
• clinical endpoints

A large percentage change can still have uncertain clinical meaning.

Transient Changes May Not Produce Durable Outcomes

A biomarker can increase for a short period after administration.

Researchers should determine:

• how quickly the increase appears
• how long it lasts
• whether repeated administration changes the pattern
• whether functional outcomes follow the same timeline

Repeated Biomarker Elevation Does Not Establish Long-Term Benefit

Maintaining an elevated laboratory measurement over weeks or months can show sustained biochemical exposure.

It does not independently establish healthier ageing, disease prevention, or improved survival.

Metabolite Changes May Reflect Processing Rather Than Effect

An intervention may increase metabolites because the body absorbed and processed the compound.

This can provide useful pharmacological information.

It does not necessarily mean that the resulting metabolic pathway change produced a clinically important effect.

NAD+ Precursors Produce Multiple Metabolites

NR, NMN, nicotinamide, and other NAD-related compounds can enter interconnected metabolic pathways.

Measured changes may include:

• NAD+
• NADH
• nicotinamide
• methylated nicotinamide metabolites
• other pathway intermediates

Changes across the pathway should not all be described as equivalent biological effects.

Enzyme Activity Is a Mechanistic Endpoint

NAD+ participates in the activity of enzymes involved in metabolism and signaling.

A change in enzyme-related activity may support a mechanistic hypothesis.

It does not establish a clinical outcome without further evidence.

Sirtuin-Related Findings Require Careful Translation

NAD+-dependent enzymes such as sirtuins are frequently discussed in ageing research.

Experimental changes in sirtuin activity or related pathways do not automatically establish:

• slower human ageing
• longer lifespan
• improved physical function
• reduced disease incidence

PARP Activity Is Another Separate Research Question

NAD+ also participates in poly(ADP-ribose) polymerase-related processes.

Changes in these pathways can be relevant to DNA-damage responses and cellular biology.

They should not be converted automatically into claims about improved DNA repair or longevity in humans.

Mitochondrial Biomarkers Do Not Establish Mitochondrial Performance

Researchers may measure gene expression, metabolites, respiratory markers, or mitochondrial-related proteins.

Each provides a partial view.

Functional outcomes may require measurements such as:

• oxygen consumption
• exercise capacity
• muscle performance
• ATP-related measures

No one biomarker describes complete mitochondrial function.

Gene-Expression Changes Are Not Clinical Outcomes

An intervention may alter the expression of genes involved in metabolism or stress responses.

Gene expression is an upstream biological measurement.

It does not establish that the encoded proteins changed sufficiently or that a meaningful physiological outcome followed.

Inflammatory Biomarkers Require Context

NAD-related studies may measure inflammatory markers.

Inflammation is complex and can vary with:

• infection
• exercise
• body composition
• time of day
• chronic conditions
• medications

A change in one inflammatory marker should not automatically be described as a broad anti-inflammatory clinical effect.

Metabolic Biomarkers Are Not the Same as Clinical Metabolic Outcomes

Studies may measure:

• glucose
• insulin
• lipids
• metabolites
• insulin-sensitivity indices

A statistically detectable change in one laboratory measurement does not automatically establish prevention or treatment of a metabolic disease.

Vascular Biomarkers Require Outcome Matching

Some human NAD-related studies investigate blood pressure, arterial stiffness, endothelial function, or other vascular measurements.

These endpoints can be useful but should not automatically be described as reductions in cardiovascular events.

Exercise Biomarkers Are Not Exercise Performance

A study may observe changes in:

• lactate
• metabolites
• oxygen-related variables
• muscle molecular markers

These do not establish improved endurance, strength, or recovery unless those outcomes were measured directly.

Recovery Is a Human Functional Concept

Recovery can involve:

• return of strength
• reduction in soreness
• restoration of performance
• return to baseline function
• subjective readiness

A change in NAD+ concentration does not automatically establish faster recovery.

Cognitive Biomarkers Do Not Establish Cognitive Improvement

Changes in metabolites or imaging variables may contribute to neurological research.

Claims about cognition require validated human cognitive testing or clinically relevant neurological endpoints.

Surrogate Endpoints Require Validation

A surrogate endpoint is used as a substitute for a direct clinical endpoint when evidence supports that relationship.

Not every NAD-related biomarker is an established surrogate for:

• healthy ageing
• fatigue
• physical recovery
• cognition
• longevity

A Correlation Does Not Establish an Intervention Effect

An observational study may find that people with one NAD-related measurement differ in health characteristics from people with another level.

This does not establish that changing the biomarker will change the outcome.

Confounding factors may include:

• age
• diet
• fitness
• body composition
• disease
• medication use

Association With Age Does Not Establish Cause of Ageing

Even when a biomarker changes with age, the change may be:

• a cause
• a consequence
• a compensatory response
• an unrelated correlate

Human intervention studies are needed to test causal hypotheses.

Preclinical Biomarker Relationships May Not Translate

Rodent studies may show close relationships between NAD+ levels and functional outcomes.

Translation may differ because of:

• species biology
• dose
• tissue metabolism
• lifespan
• experimental conditions

Rodent NAD+ Restoration Does Not Establish Human Age Reversal

An intervention that restores a biochemical measurement in an aged animal model does not establish reversal of human ageing.

Human ageing outcomes require direct human evidence.

The Same Biomarker Can Have Different Meanings in Different Tissues

A rise in NAD+ in blood cells may not produce the same functional significance as a rise in skeletal muscle or another tissue.

Tissue context is therefore essential.

Study Duration Affects Interpretation

A biomarker may respond within days while functional changes require weeks or months.

A short trial may therefore be capable of establishing target engagement but not the downstream outcome.

Small Studies Can Overestimate Biomarker-Outcome Relationships

Small studies can produce unstable estimates.

Replication in larger populations helps determine whether:

• the biomarker response is consistent
• the functional effect is reproducible
• subgroups differ
• rare safety findings emerge

Primary and Secondary Endpoints Must Be Distinguished

A study may be designed primarily to assess NAD+ levels while collecting functional endpoints as exploratory measurements.

Exploratory findings generally provide weaker evidence than a trial designed and powered specifically for the clinical outcome.

Post Hoc Biomarker Associations Need Confirmation

Researchers may discover after a trial that participants with larger NAD+ increases appeared to have different functional outcomes.

This can generate a hypothesis.

It does not establish a causal exposure-response relationship without further investigation.

Biochemical Success Can Coexist With Clinical Null Results

This pattern has appeared repeatedly in human NAD+ precursor research.

Studies may show that the intervention increases NAD-related metabolites while producing:

• no detectable change in some functional endpoints
• mixed changes across endpoints
• effects limited to selected subgroups

The null clinical findings remain part of the evidence.

Clinical Outcomes Must Be Measured Directly

If the proposed outcome is physical energy, the study should use a relevant validated measure.

If the proposed outcome is recovery, recovery should be measured.

If the proposed outcome is healthy ageing, the trial should use defined human ageing-related outcomes.

Human Evidence Should Be Evaluated Study by Study

The broader evaluation framework is explained in how human NAD+ research should be evaluated.

Different compounds, tissues, assays, and endpoints should not be merged into one general conclusion.

Current Reviews Support This Evidence Boundary

Recent reviews of NAD+ precursor supplementation report that human studies often demonstrate biochemical changes more consistently than broad clinical effects.

The 2025 review of NAD+ precursor supplementation and human ageing emphasizes that human clinical efficacy remains limited and that tissue-specific human evidence is still sparse.

Final Perspective

NAD+ biomarker changes can provide important evidence that an intervention altered NAD-related metabolism, but biomarkers are intermediate measurements rather than automatic proof of a human clinical outcome.

A rise in NAD+, a metabolite, enzyme signal, mitochondrial marker, inflammatory marker, or other laboratory measurement should be interpreted according to the tissue measured, analytical method, magnitude, duration, study design, and relationship to predefined functional endpoints.

Accurate coverage should distinguish biochemical target engagement from demonstrated human outcomes and should not convert NAD-related biomarker changes into claims about energy, recovery, cognition, healthy ageing, disease modification, or longevity without direct supporting clinical evidence.